
AdaptHealth (AHCO) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
580.5M
Gross Profit
-77.0M
-13.26%
Operating Income
23.2M
3.99%
Net Income
-6.1M
-1.05%
EPS (Diluted)
$-0.05
Balance Sheet Metrics
Total Assets
4.4B
Total Liabilities
2.9B
Shareholders Equity
1.6B
Debt to Equity
1.82
Cash Flow Metrics
Operating Cash Flow
95.3M
Free Cash Flow
-58.0K
Revenue & Profitability Trend
AdaptHealth Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 3.3B | 3.2B | 3.0B | 2.5B | 1.1B |
Cost of Goods Sold | 2.6B | 2.7B | 2.6B | 2.0B | 898.6M |
Gross Profit | 681.1M | 479.6M | 417.4M | 445.6M | 157.8M |
Gross Margin % | 20.9% | 15.0% | 14.1% | 18.2% | 14.9% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 359.2M | 190.1M | 162.1M | 167.5M | 89.3M |
Other Operating Expenses | - | - | - | -10.6M | -14.3M |
Total Operating Expenses | 359.2M | 190.1M | 162.1M | 156.9M | 75.1M |
Operating Income | 276.8M | 232.4M | 190.4M | 225.6M | 71.3M |
Operating Margin % | 8.5% | 7.3% | 6.4% | 9.2% | 6.8% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | 126.7M | 130.3M | 109.4M | 95.2M | 41.4M |
Other Non-Operating Income | -14.1M | -825.9M | 16.9M | 60.5M | -236.0M |
Pre-tax Income | 136.0M | -723.8M | 97.9M | 191.0M | -206.0M |
Income Tax | 41.2M | -49.0M | 24.8M | 32.8M | -12.0M |
Effective Tax Rate % | 30.3% | 0.0% | 25.3% | 17.2% | 0.0% |
Net Income | 94.8M | -674.8M | 73.1M | 158.2M | -194.1M |
Net Margin % | 2.9% | -21.1% | 2.5% | 6.4% | -18.4% |
Key Metrics | |||||
EBITDA | 639.4M | 585.6M | 541.3M | 481.8M | 157.2M |
EPS (Basic) | $0.62 | $-5.06 | $0.47 | $1.12 | $-1.23 |
EPS (Diluted) | $0.61 | $-5.31 | $0.33 | $0.67 | $-1.23 |
Basic Shares Outstanding | 133756000 | 134156000 | 134175000 | 126306000 | 52488000 |
Diluted Shares Outstanding | 133756000 | 134156000 | 134175000 | 126306000 | 52488000 |
Income Statement Trend
AdaptHealth Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 109.7M | 77.1M | 46.3M | 149.6M | 100.0M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 408.0M | 388.9M | 359.1M | 359.9M | 171.1M |
Inventory | 139.8M | 113.6M | 127.8M | 123.1M | 58.8M |
Other Current Assets | 45.4M | 69.3M | 52.1M | 37.4M | - |
Total Current Assets | 755.8M | 649.0M | 585.3M | 670.1M | 363.3M |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.0B | 954.0M | 899.0M | 731.7M | 184.2M |
Goodwill | 5.5B | 5.6B | 7.3B | 7.2B | 2.1B |
Intangible Assets | 105.5M | 130.2M | 162.8M | 202.2M | 116.1M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 332.1M | 367.0M | 304.2M | 319.3M | 224.9M |
Total Non-Current Assets | 3.7B | 3.9B | 4.6B | 4.6B | 1.5B |
Total Assets | 4.5B | 4.5B | 5.2B | 5.3B | 1.8B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 284.6M | 211.5M | 222.5M | 248.0M | 191.0M |
Short-term Debt | 60.5M | 91.8M | 67.2M | 66.9M | 30.4M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 33.5M | 14.7M | 19.9M | 43.2M | 126.4M |
Total Current Liabilities | 567.0M | 537.0M | 456.2M | 499.8M | 422.1M |
Non-Current Liabilities | |||||
Long-term Debt | 2.1B | 2.2B | 2.3B | 2.3B | 776.6M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 272.0M | 302.1M | 305.5M | 322.5M | 220.1M |
Total Non-Current Liabilities | 2.3B | 2.5B | 2.6B | 2.7B | 1.1B |
Total Liabilities | 2.9B | 3.0B | 3.1B | 3.2B | 1.5B |
Equity | |||||
Common Stock | 13.0K | 13.0K | 13.0K | 13.0K | 9.0K |
Retained Earnings | -562.2M | -652.6M | 26.3M | -43.0M | -199.2M |
Treasury Stock | 25.5M | 43.3M | 14.0M | 0 | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.6B | 1.5B | 2.2B | 2.1B | 280.8M |
Key Metrics | |||||
Total Debt | 2.1B | 2.3B | 2.3B | 2.4B | 807.0M |
Working Capital | 188.8M | 112.0M | 129.1M | 170.2M | -58.8M |
Balance Sheet Composition
AdaptHealth Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 94.8M | -674.8M | 73.1M | 158.2M | -194.1M |
Depreciation & Amortization | 365.3M | 382.8M | 351.2M | 258.1M | 82.4M |
Stock-Based Compensation | 14.9M | 22.5M | 22.4M | 25.3M | 18.7M |
Working Capital Changes | -53.4M | -4.8M | -126.1M | -184.1M | 87.7M |
Operating Cash Flow | 503.6M | -293.5M | 375.9M | 284.9M | 73.9M |
Investing Activities | |||||
Capital Expenditures | -306.1M | -337.5M | -391.4M | -203.3M | -39.8M |
Acquisitions | -9.5M | -19.7M | -19.0M | -1.6B | -769.3M |
Investment Purchases | 0 | -128.0K | -731.0K | -1.1M | -8.7M |
Investment Sales | - | - | 0 | 0 | 2.0M |
Investing Cash Flow | -310.3M | -357.3M | -411.2M | -1.8B | -815.7M |
Financing Activities | |||||
Share Repurchases | 0 | -29.3M | -14.0M | 0 | -44.3M |
Dividends Paid | - | - | - | 0 | 0 |
Debt Issuance | 253.5M | 50.0M | 0 | 2.3B | 941.3M |
Debt Repayment | -433.3M | -101.8M | -36.2M | -869.4M | -586.5M |
Financing Cash Flow | -200.7M | -95.1M | -70.2M | 1.6B | 648.5M |
Free Cash Flow | 235.8M | 143.2M | -17.6M | 72.4M | 155.9M |
Net Change in Cash | -7.4M | -746.0M | -105.5M | 45.5M | -93.3M |
Cash Flow Trend
AdaptHealth Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
16.83
Forward P/E
10.69
Price to Book
0.76
Price to Sales
0.38
PEG Ratio
-0.73
Profitability Ratios
Profit Margin
2.49%
Operating Margin
7.10%
Return on Equity
5.51%
Return on Assets
3.70%
Financial Health
Current Ratio
1.06
Debt to Equity
122.33
Beta
1.62
Per Share Data
EPS (TTM)
$0.54
Book Value per Share
$12.00
Revenue per Share
$24.06
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
ahco | 1.3B | 16.83 | 0.76 | 5.51% | 2.49% | 122.33 |
Abbott Laboratories | 234.4B | 16.89 | 4.63 | 30.93% | 32.43% | 26.50 |
Boston Scientific | 144.2B | 57.93 | 6.43 | 11.55% | 13.55% | 53.09 |
Artivion | 2.0B | -128.28 | 4.61 | -5.02% | -4.43% | 62.81 |
Enovis | 1.8B | -2.14 | 0.71 | -28.25% | -37.80% | 56.75 |
Novocure | 1.6B | -9.40 | 4.69 | -48.07% | -27.13% | 200.39 |
Financial data is updated regularly. All figures are in the company's reporting currency.